May 30, 2024 11:02 AM EDT
R&D
Pharma

No­var­tis ends de­vel­op­ment of KRAS drug, cit­ing 'in­creas­ing op­tions avail­able'

Kyle LaHucik

Senior Reporter

No­var­tis will stop de­vel­op­ing a KRAS lung can­cer drug that had made it to Phase 3 test­ing, a spokesper­son con­firmed to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Se­cre­tive Tree­line Bio­sciences dis­clos­es $421M fi­nanc­ing in fil­ing

House’s promi­nent Chi­na crit­ic Jim Mc­Gov­ern leads op­po­si­tion to Biose­cure Act: ‘I would pre­fer to go back to the ...

RNA gene ther­a­py start­up Shape hunts for new CEO as Se­ries C awaits

Sage shakes up se­nior man­age­ment, slash­es pipeline, sheds 33% of staff

FDA de­lays col­orec­tal can­cer de­ci­sion for Am­gen's Lumakras, a set­back in race with Bris­tol My­ers

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times